Reduced Foxp3 expression is advantageous for enhancing the therapeutic benefit of patients on anti-cancer medications, as miR-4281 directly binds to the Foxp3 promoter, upregulates the expression of Foxp3 protein, and promotes the immunosuppressive role of Foxp3+Treg (15). Here, FOXP3 is linked to cancer.